Hong Kong E changes and Clearing Limi ed and The S ock E change of Hong Kong Limi ed ake no responsibili for he con en s of his anno. ncemen, make no representation as o is acc. rac or completeness and e press disclaim an liabili ha soer er for an loss ho soer er arising from or in reliance. pon he hole or an par of he con en s of his anno. ncemen.



## SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. (深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability) (Stock code: 9989)

## **INSIDE INFORMATION ANNOUNCEMENT**

Thi a ce e i ade bKShe he He ali k Pha ace ical G C ., L d. (he **Company** ge he i h i b idia ie, he **Group**), i a he I ide I f ai P i i de Pa XIVA f he See i ie a d Fi e O di a ce (Cha e 571 f he La f H g K g) a d R le 13.09(2)(a) f he R le G e i g he Li i g f See i ie The S ck E cha ge f H g K g Li i ed (Listing **Rules**).

The b a d f di ec (he **Directors**) f he C  $a_{y}K(he Board)$  i he i f he ha eh lde f he C  $a_{y}K(he Shareholders)$  a d e ial i e ha, Techd Pha a I al KS.R.L., a h ll K ed i b idia K f he C  $a_{y}K($  Techdow Italy), i i ec ed ha e bee def a ded b K a c i i al K dica e a a e i f elec f a d, i 1 i g a a i f a i a el K 11.7 illi e (he Incident). The C  $a_{y}K$  if i ke ed he I cide he lice af e di c e i g he f a d. The lice ha e i e, he C  $a_{y}K$  if i ll K c e a i g i h he lice i e iga i a d aki g e e Keff i i e he lice he lice i g

The a age e f he C a Kha [Kale ed he B a d, i de e de -e eo i e Di ec a d he a di c i ee f he B a d f he I cide, a d i eli i a Ka e e i dica e ha he I cide i a i la ed e e . The a age e f he C a Kc fi ed ha he C a K d c i a d e a i e a i al. The C a K a age e i e i e i g he I cide ca efi l Ka d ha ac i e K ad ed ea e ha ce i i e al c l a age e, c a eg e a ce a d i ka a e e . The i e i f e i c ce he C a K a age e, h ha e e el Techd I al K ha dle he I cide . A he i e iga i i he I cide i g i g, he i c e i ill ce ai, a d a K ha e e ial i ac he C a K fi a cial a e e f he Kea e ded 31 Dece be 2023 (FY2023).

The C  $a_{y}Ki$  i ighe i e igai fhe I cide ihge a c ce a d ill c e a e fi l K ihhe lice e l e he ca e a d e c e  $a_{y}Kl$  e ih dela K

The B a d c ide ha he e all e a i f he G , a a h le e a i al a d i fi a cial i i e a i lid.

The C a K ill ake fi he a ce e () kee he Sha eh lde a d e ial i e i f ed fa K ig ifica de el e i e ec f he I cide a a d he a ia e. Sha eh lde a d e ial i e f he C a Ka e ad i ed ead ca efi llK he a al e 1 a ce e f he C a Kf FY2023 (Annual Results), hich i e ec ed be bli hed i Ma ch 2024 a he e i e f he Li i g R le, a d a K e ial fi a i g a ce e i ela i he A al Re 1.

Shareholders and potential investors of the Company are reminded that the information provided in this announcement is based on the currently available information to the Board. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

BK de f he B a d Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Li Li Chairman

She he, he PRC Ja<sub>1</sub> a<sub>y</sub>K15, 2024

As a he dae of his anno. ncemen, he e. ec. ive direc ors of he Compan are Mr. Li Li, Ms. Li Tan, Mr. Shan Y. and Mr. Zhang Ping; and he independen non-e. ec. ive direc ors of he Compan are Dr. L. Ch. an, Mr. H. ang Peng and Mr. Yi Ming.